ArticleTropical medicine and infectious disease2021
An Update on Cholera Immunity and Current and Future Cholera Vaccines.
Article in Tropical medicine and infectious disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Long-Term Kinetics of Serological Antibodies againstInternational journal of environmental research and public health · 2022Pooled it
- Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response-A Randomized, Placebo-Controlled Trial.Clinical pharmacology and therapeutics · 2026Trial
- Co-administration of oral killed whole-cell recombinant cholera toxin B-subunit vaccine (WC-rCTB) and live Salmonella Typhi Ty21a vaccine: a prospective randomized open-label trial.Journal of travel medicine · 2026Trial
- Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule.Vaccines · 2026Article
- Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study.Vaccines · 2026Article
- Oral Cholera Vaccines as Transmission-Interrupting Tools for Cholera Control: A Narrative Review.Infection and drug resistance · 2026Review
- Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.Frontiers in pediatrics · 2026Article
- Investigation of a suspected cholera outbreak within a closed community of trainees at a college in Hammanskraal, Gauteng Province, South Africa, June 2023.BMC infectious diseases · 2025Article
- Dynamics of IgM and IgA Antibody Response Profile AgainstInternational journal of molecular sciences · 2025Article
- Impact of a multi-pronged cholera intervention in an endemic setting.PLoS neglected tropical diseases · 2025Article
- Risk Communication and Community Engagement (RCCE) implementations to control cholera outbreak in Oromia region, Ethiopia.Tropical medicine and health · 2025Article
- Cholera outbreaks: Public health implications, economic burden, and preventive strategies.AIMS public health · 2025Review
- Impact of a multi-pronged cholera intervention in an endemic setting.medRxiv : the preprint server for health sciences · 2024Article
- Water pollution, cholera, and the role of probiotics: a comprehensive review in relation to public health in Bangladesh.Frontiers in microbiology · 2024Review
- Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.The Lancet regional health. Southeast Asia · 2023Article
- Intracellular Expression of CTB inJournal of microbiology and biotechnology · 2023Article
- Bioinformatics analysis of structural protein to approach a vaccine candidate against Vibrio cholerae infection.Immunogenetics · 2023Article
- Review
- B-Cell Epitope Mapping of theInternational journal of molecular sciences · 2022Article
- InactivatedJournal of microbiology and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Individual resistance to cholera infection and disease depends on both innate host factors and adaptive immunity acquired by a previous infection or vaccination. Locally produced, intestinal-mucosal secretory IgA (SIgA) antibodies against bacterial surface lipopolysaccharide (LPS) O antigens and/or secreted cholera toxins are responsible for the protective adaptive immunity, in conjunction with an effective mucosal immunologic memory that can elicit a rapid anamnestic SIgA antibody response upon re-exposure to the antigen/pathogen even many years later. Oral cholera vaccines (OCVs), based on inactivated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.